Hans Thalsgard Schambye

Title: Hans Thalsgard Schambye: Innovator in G-CSF Polypeptides

Introduction

Hans Thalsgard Schambye is a notable inventor based in Frederiksberg, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of polypeptide conjugates that exhibit G-CSF activity. His innovative work has the potential to improve therapeutic outcomes for patients.

Latest Patents

One of Schambye's key patents is focused on G-CSF polypeptides and conjugates. The invention relates to polypeptide conjugates that comprise a polypeptide exhibiting G-CSF activity. These polypeptides have an amino acid sequence that differs from human G-CSF by at least one specified introduced and/or removed amino acid residue. The conjugates include an attachment group for a non-polypeptide moiety, which may enhance their properties. The attachment group can be a lysine, cysteine, aspartic acid, or glutamic acid residue, or even a glycosylation site. The non-polypeptide moiety may include polymers such as polyethylene glycol or oligosaccharides. This innovative conjugate offers improved properties, including increased biological half-life and reduced side effects.

Career Highlights

Throughout his career, Schambye has worked with various companies, including Maxygen Holdings Ltd. and Christian Karsten Hansen. His experience in these organizations has contributed to his expertise in the field of biotechnology and patent development.

Collaborations

Some of his notable coworkers include Christian Hansen and Jan Moller Mikkelsen. Their collaboration has likely fostered an environment of innovation and creativity in their respective projects.

Conclusion

Hans Thalsgard Schambye is a distinguished inventor whose work on G-CSF polypeptides and conjugates has the potential to significantly impact the field of biotechnology. His contributions reflect a commitment to advancing medical science and improving patient care.